IL-13Rα2 UCAR-T cells

IL-13Rα2 UCAR-T cells are allogeneic (universal) chimeric antigen receptor T cell therapies engineered to target the interleukin-13 receptor subunit alpha 2 (IL-13Rα2), a protein overexpressed on the surface of various solid tumors, including glioblastoma and melanoma. These CAR-T cells are designed to recognize and bind specifically to IL-13Rα2-expressing tumor cells, leading to their targeted destruction. The therapy leverages genetically modified T lymphocytes equipped with a synthetic receptor that combines an anti–IL-13Rα2 single-chain variable fragment (scFv) or mutated interleukin 13 ligand with intracellular signaling domains such as CD28 or 4‑1BB and CD3ζ. This approach aims to enhance anti-tumor immune responses while minimizing off-tumor toxicity due to the limited expression of IL‑13Rα2 in normal tissues. Clinical studies have demonstrated safety and promising activity in patients with recurrent high-grade glioma, particularly glioblastoma[1][3][4]. Research is ongoing for other solid tumors expressing this target.

Other names

IL-13Rα2-targeted CAR-T cellsIL13Ra2 CAR-T cellsIL-13Ra2 CAR-T cellsIL 13Ra2 CAR-T cellsInterleukin-13 receptor subunit alpha-2 chimeric antigen receptor T cellsInterleukin13 receptor subunit alpha-2 chimeric antigen receptor T cellsInterleukin 13 receptor subunit alpha-2 chimeric antigen receptor T cells